Oncology · ChemotherapySafety Signalregulatorynear-term

Sunny Pharmtech Issues Recall of Cyclophosphamide Injection Due to Contamination

Importance8/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/25/2026, 6:31:46 AM

Assessment confidence: 61% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The recall of Cyclophosphamide Injection due to contamination poses significant risks to patient safety and treatment continuity in oncology. This situation may disrupt supply chains and create opportunities for competitors to capture market share. Regulatory context from FDA (Khong Guan Corporation Issues Expanded Recall of Glutinous Rice Balls With Black Sesame Filling to Include Black & White Glutinous Rice Balls With Black Sesame Filling Due to Undeclared Peanuts) supports the near-term read. Assessment grounded in 28 ranked evidence items (10 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this recall on supply chains and consider alternative therapies for affected patients. The strongest clinical anchor is A Study Comparing Pre-filled Safety Syringe and an Autoinjector for SHR-1703 Injection in Healthy Participants (ClinicalTrials.gov), mechanism alignment (io ). In Oncology · Chemotherapy, 7 regulatory and 6 competitive items passed relevance filtering for competing pharma companies.

Competitive Pressure

The most relevant competitive pressure comes from [Ad hoc announcement pursuant to Art. (Roche) — sponsor/company relevance (roche). Secondary pressure from [Ad hoc announcement pursuant to Art.. This recall may impact the availability of Cyclophosphamide in the market, potentially affecting competitors and patient treatment options.

Regulatory Outlook

Regulatory risk is concentrated around Khong Guan Corporation Issues Expanded Recall of Glutinous Rice Balls With Black Sesame Filling to Include Black & White Glutinous Rice Balls With Black Sesame Filling Due to Undeclared Peanuts (FDA). Regulatory pathway relevance (bla). The contamination issue raises serious compliance concerns, necessitating close monitoring of regulatory responses and potential impacts on future approvals or product labeling.

Key Risks

Elevated high regulatory exposure for competing pharma companies could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.

Key Opportunities

The recall could lead to a temporary shortage of Cyclophosphamide, affecting revenue streams for Sunny Pharmtech and potentially increasing demand for alternative therapies from competitors.
Upside for competing pharma companies may improve if A Study Comparing Pre-filled Safety Syringe and an Autoinjector for SHR-1703 Injection in Healthy Participants (ClinicalTrials.gov) delivers favorable follow-through.
Khong Guan Corporation (Union City, CA) is recalling specific lots of “Glutinous Rice Balls with Black Sesame Filling” and “Black & White Glutinous Rice Balls with Black Sesame Filling” in their recall expansion because they may contain undeclared peanuts.
Upside for competing pharma companies may improve if Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC) (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the impact of this recall on supply chains and consider alternative therapies for affected patients.

What Would Change This Assessment

This becomes more urgent if Monitor for updates on the recall process and any reported adverse events related to the contaminated lots.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Khong Guan Corporation Issues Expanded Recall of Glutinous Rice Balls With Black Sesame Filling to Include Black & White Glutinous Rice Balls With Black Sesame Filling Due to Undeclared Peanuts
FDAhigh relevance
Regulatory pathway relevance (bla)
FDA document
View source
Khong Guan Corporation Issues Recall of Glutinous Rice Balls With Black Sesame Filling Due to Undeclared Peanuts
FDAhigh relevance
Regulatory pathway relevance (bla)
FDA document
View source
BAXTER ISSUES VOLUNTARY NATIONWIDE RECALL OF CEFAZOLIN IN DEXTROSE INJECTION, USP, 2G / 100ML (20MG / ML) SINGLE-DOSE INFUSION BAG IN 100ML DUE TO PARTICULATE MATTER FOUND IN SOLUTION
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Beekeeper’s Naturals Issues Voluntary Nationwide Recall of Beekeeper’s Naturals Saline Nasal Spray Sold Through Amazon Due to Microbial Contamination
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Convenience Kit Correction: Medline Issues Correction for Kits Containing Huons Bupivacaine Hydrochloride in Dextrose Injection, USP
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Sunny Pharmtech, Inc.
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Convenience Kit Correction: Arrow International Issues Correction for Convenience Kits Containing Recalled Huons Lidocaine and Bupivacaine and Saline
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

A Study Comparing Pre-filled Safety Syringe and an Autoinjector for SHR-1703 Injection in Healthy Participants
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View source
Long-Term Real-World Evidence Study to Evaluate Effectiveness, Persistence, Adherence, Safety and Tolerability of Long-acting Cabotegravir Plus Rilpivirine.
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View source
The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Met
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Electroacupuncture and Exercise for Chemotherapy-Induced Peripheral Neuropathy (CIPN)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment
Concerns Raised Over Hepatotoxicity of Epimedium brevicornu Maxim.
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves PADCEV plus Keytruda for Muscle-Invasive Bladder Cancer Treatment
Humanexa Signalsmedium relevance
Moderate corpus alignment

Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Integrating machine learning and pharmacology reveals NF-κB-mediated inflammatory regulation by Shuanghuanglian injection in acute lung injury.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JMKX003002 in Chinese healthy participants: a randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, an
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and safety of oral finasteride versus dutasteride in moderate-to-severe androgenetic alopecia in males based on trichoscopic and laboratory findings: a clinical comparison in Iran.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Analysis of efficacy and safety of transarterial embolization sequential microwave ablation for hepatic hemangioma.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

competing pharma companies

Commercial impact

medium

The recall could lead to a temporary shortage of Cyclophosphamide, affecting revenue streams for Sunny Pharmtech and potentially increasing demand for alternative therapies from competitors.

Regulatory impact

high

The contamination issue raises serious compliance concerns, necessitating close monitoring of regulatory responses and potential impacts on future approvals or product labeling.

What to watch

Monitor for updates on the recall process and any reported adverse events related to the contaminated lots.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.